FrancophonIA/ELRC3.0 huggingface dataset:
English: EU/1/12/772/004 multipack with 10 bags
Slovenian: EU/1/12/772/003 skupno pakiranje po 5 vreč EU/1/12/772/004 skupno pakiranje po 10 vreč
English: Medicinal product subject to medical prescription.
Slovenian: IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: The recommended dose is 210 mg given once a week for the first 3 weeks and then every 2 weeks.
Slovenian: Priporočeni odmerek je 210 mg enkrat na teden prve tri tedne, nato pa vsaka dva tedna.
English: The doctor may decide to stop treatment if the condition does not improve after 12 to 16 weeks.
Slovenian: Zdravnik se lahko odloči za prenehanje zdravljenja, če se stanje po 12 do 16 tednih ne izboljša.
English: What measures are being taken to ensure the safe and effective use of Kyntheum?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Kyntheum?
English: The full EPAR for Kyntheum can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Kyntheum je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Kyntheum
Slovenian: Druge informacije o zdravilu Kyntheum
English: This is a summary of the European public assessment report (EPAR) for Kyntheum.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Kyntheum.
English: Although there have been recent advances in the treatment of plaque psoriasis, there remains a need for new treatment options.
Slovenian: Čeprav je v zadnjem času prišlo do napredka pri zdravljenju psoriaze v plakih, še vedno ostaja potreba po novih možnostih zdravljenja.
English: Studies have shown that Kyntheum was highly effective at clearing the skin and the positive effects were maintained with continued use.
Slovenian: Študije so pokazale, da je zdravilo Kyntheum zelo učinkovito pri čiščenju kože, pozitivni učinki pa so se z nadaljnjo uporabo ohranili.
English: The most common side effects with Kyntheum (which may affect more than 1 in 100 people) are joint pain, headache, tiredness, diarrhoea and oropharyngeal pain (pain in the mouth and throat).
Slovenian: Najpogostejši neželeni učinki zdravila Kyntheum (ki se lahko pojavijo pri več kot 1 bolniku od 100) so bolečine v sklepih, glavobol, utrujenost, driska in orofaringealna bolečina (bolečina v ustih in grlu).
English: After training, patients may inject Kyntheum if their doctor considers it appropriate.
Slovenian: Bolniki si lahko po opravljenem usposabljanju sami injicirajo zdravilo Kyntheum, če zdravnik meni, da je to primerno.
English: The European Medicines Agency therefore decided that Kyntheum's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Kyntheum večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
English: Kyntheum has been shown to be effective at treating plaque psoriasis in 3 main studies involving over 4,300 patients who required systemic treatment.
Slovenian: Zdravilo Kyntheum se je pokazalo kot učinkovito pri zdravljenju psoriaze v plakih v treh glavnih študijah, ki so vključevale več kot 4 300 bolnikov, ki so potrebovali sistemsko zdravljenje.
English: The active substance in Kyntheum, brodalumab, is a monoclonal antibody, a protein designed to block the activity of certain substances called interleukins 17 (A, F and A/F), which are messengers in the body's immune system (the body's natural defences).
Slovenian: Zdravilna učinkovina zdravila Kyntheum, brodalumab, je monoklonsko protitelo, beljakovina, zasnovana tako, da zavira delovanje določenih snovi, imenovanih interlevkini 17 (A, F in A/F), ki so prenašalci sporočil v imunskem sistemu telesa (naravni obrambi telesa).
English: Data from one study also showed that the benefits of treatment with Kyntheum were maintained when treatment was continued for one year.
Slovenian: Podatki ene študije so pokazali tudi, da so se koristi zdravljenja z zdravilom Kyntheum ohranile, če so bolniki nadaljevali z zdravljenjem eno leto.
English: What are the risks associated with Kyntheum?
Slovenian: Kakšna tveganja so povezana z zdravilom Kyntheum?
English: What benefits of Kyntheum have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Kyntheum izkazalo v študijah?
English: What is Kyntheum and what is it used for?
Slovenian: Kaj je zdravilo Kyntheum in za kaj se uporablja?
English: By blocking the action of interleukin 17 substances, brodalumab reduces the inflammation and symptoms associated with the disease.
Slovenian: Z zaviranjem delovanja interlevkinov 17 brodalumab zmanjša vnetje in simptome, povezane z boleznijo.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kyntheum have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Kyntheum upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Also, 79% of patients given Kyntheum had clear or nearly clear skin after 12 weeks, compared with 3% of patients given placebo and 70% of patients given ustekinumab.
Slovenian: Poleg tega je imelo 79 % bolnikov, ki so prejemali zdravilo Kyntheum, po 12 tednih čisto oziroma skoraj čisto kožo v primerjavi s 3 % bolnikov, ki so prejemali placebo, in 70 % bolnikov, ki so prejemali ustekinumab.
English: Kyntheum must not be given to patients who have potentially serious infections such as tuberculosis and to patients with active Crohn's disease (an inflammatory disease affecting the gut).
Slovenian: Zdravilo Kyntheum se ne sme dajati bolnikom s potencialno resnimi okužbami, kot je tuberkuloza, in bolnikom z aktivno Crohnovo boleznijo (vnetno črevesno boleznijo).
English: Side effects are similar to those of other medicines that target interleukin molecules.
Slovenian: Neželeni učinki so podobni kot pri drugih zdravilih, ki delujejo proti interlevkinskim molekulam.
English: It is not intended to provide practical advice on how to use Kyntheum.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Kyntheum should be stopped in patients who show new symptoms of depression or anxiety or in case they worsen.
Slovenian: Zdravljenje z zdravilom Kyntheum je treba prekiniti pri bolnikih, pri katerih se pojavijo novi simptomi depresije ali anksioznosti oziroma se obstoječi poslabšajo.
English: Why is Kyntheum approved?
Slovenian: Zakaj je bilo zdravilo Kyntheum odobreno?
English: It is used in adults whose disease is moderate to severe and who require systemic treatment (treatment with medicines given by mouth or by injection).
Slovenian: Uporablja se pri odraslih z zmerno do hudo boleznijo, ki potrebujejo sistemsko zdravljenje (zdravljenje z zdravili, ki se dajejo peroralno ali z injiciranjem).
English: For the full list of all side effects and restrictions with Kyntheum, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Kyntheum glejte navodilo za uporabo.
English: Kyntheum can only be obtained with a prescription and should be used under the supervision of a doctor experienced in diagnosing and treating psoriasis.
Slovenian: Predpisovanje in izdaja zdravila Kyntheum je le na recept, zdravilo pa se mora uporabljati pod nadzorom zdravnika, ki ima izkušnje z diagnosticiranjem in zdravljenjem psoriaze.
English: Although there is no evidence of a link to the medicine, the decision to start Kyntheum in patients who have had suicidal behaviour in the past or suffered from depression or anxiety should be made after carefully looking at all the risks and benefits for that patient.
Slovenian: Čeprav ni dokazov za povezavo z zdravilom, je treba pri odločanju za začetek zdravljenja z zdravilom Kyntheum pri bolnikih, ki v preteklosti izkazovali samomorilno vedenje ali imeli depresijo ali anksioznost, skrbno pretehtati tveganja in koristi za bolnika.
English: For more information about treatment with Kyntheum, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Kyntheum preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: This compares with 6% of those given placebo and with 70% of patients given ustekinumab.
Slovenian: Ta delež je pri bolnikih, ki so prejemali placebo, znašal 6 %, pri bolnikih, ki so prejemali ustekinumab, pa 70 %.
English: Plaque psoriasis improved to a greater extent in patients treated with Kyntheum than with placebo (a dummy treatment) or with ustekinumab (another medicine for psoriasis that targets interleukin molecules).
Slovenian: Psoriaza v plakih se je pri bolnikih, ki so bili zdravljeni z zdravilom Kyntheum, izboljšala v primerjavi z bolniki, zdravljenimi s placebom (zdravilom brez zdravilne učinkovine) ali ustekinumabom (drugim zdravilom za psoriazo, ki deluje na molekule interlevkina).
English: Kyntheum is available as a solution for injection in pre-filled syringes.
Slovenian: Zdravilo Kyntheum je na voljo v obliki raztopine za injiciranje v napolnjeni injekcijski brizgi.
English: Interleukins 17 are involved in the process of inflammation that causes plaque psoriasis.
Slovenian: Interlevkini 17 so vključeni v vnetni proces, ki povzroča psoriazo v plakih.
English: For practical information about using Kyntheum, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Kyntheum naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Looking at the results of the 3 studies together, 85% of patients treated with Kyntheum obtained a 75% reduction in PASI scores (a measure of disease severity and area of skin affected) after 12 weeks.
Slovenian: Skupna analiza rezultatov treh študij je pokazala, da je po 12 tednih prišlo do 75-odstotnega znižanja ocene PASI (merilo za resnost bolezni in površino prizadete kože) pri 85 % bolnikov, zdravljenih z zdravilom Kyntheum.
English: Kyntheum is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin.
Slovenian: Zdravilo Kyntheum se uporablja za zdravljenje psoriaze v plakih, tj. bolezni, ki povzroča rdeče, luskaste spremembe na koži.
English: There have been some reports of suicidal behaviour in patients taking the medicine.
Slovenian: Pri bolnikih, ki so jemali to zdravilo, so poročali o nekaj primerih samomorilnega vedenja.
English: How is Kyntheum used?
Slovenian: Kako se zdravilo Kyntheum uporablja?
English: How does Kyntheum work?
Slovenian: Kako zdravilo Kyntheum deluje?
English: Kyntheum contains the active substance brodalumab.
Slovenian: Zdravilo Kyntheum vsebuje zdravilno učinkovino brodalumab.
English: The full EPAR for Kisplyx can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Kisplyx je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Kisplyx?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Kisplyx?
English: The recommended dose is 18 mg (made up of one 10 mg capsule and two 4 mg capsules) once a day at the same time each day in combination with 5 mg of everolimus once a day.
Slovenian: Priporočen odmerek je 18 mg (ki ga sestavlja ena 10 mg kapsula in dve 4 mg kapsuli) enkrat dnevno ob istem času v kombinaciji s 5 mg everolimusa enkrat na dan.
English: Kisplyx is available as capsules (4 mg and 10 mg).
Slovenian: Na voljo je v obliki kapsul (4 mg in 10 mg).
English: This is a summary of the European public assessment report (EPAR) for Kisplyx.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Kisplyx.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Kisplyx's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zato zaključil, da so koristi zdravila Kisplyx večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: Patients who took the combination of Kisplyx and everolimus lived for an average of 14.6 months without their disease getting worse, compared with 7.4 months for the patients who took Kisplyx alone and 5.5 months for the patients who took everolimus alone.
Slovenian: Bolniki, ki so prejemali kombinacijo zdravila Kisplyx in everolimusa, so živeli povprečno 14,6 meseca, ne da bi se jim bolezen poslabšala, v primerjavi s 7,4 meseca pri bolnikih, ki so prejemali samo zdravilo Kisplyx, in 5,5 meseca pri bolnikih, ki so prejemali samo everolimus.
English: Other information about Kisplyx
Slovenian: Druge informacije o zdravilu Kisplyx
English: What is Kisplyx and what is it used for?
Slovenian: Kaj je zdravilo Kisplyx in za kaj se uporablja?
English: Treatment is given for as long as the patient benefits from it or until side effects become unacceptable.
Slovenian: Zdravilo se daje, dokler je za bolnika koristno oziroma do pojava nesprejemljivih neželenih učinkov.
English: It is not intended to provide practical advice on how to use Kisplyx.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What are the risks associated with Kisplyx?
Slovenian: Kakšna tveganja so povezana z zdravilom Kisplyx?
English: Kisplyx can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in using cancer medicines.
Slovenian: Predpisovanje in izdaja zdravila Kisplyx je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
English: By blocking these enzymes, lenvatinib can block the formation of new blood vessels, cutting off the blood supply that keeps cancer cells growing, and reduce the growth of the cancer.
Slovenian: Z zaviranjem teh encimov lahko lenvatinib zavira nastajanje novih krvnih žil in prekine dotok krvi, ki omogoča rast rakastih celic, ter zmanjša rast raka.
English: What benefits of Kisplyx have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Kisplyx izkazalo v študijah?
English: Kisplyx must not be taken by breastfeeding women.
Slovenian: Zdravilo Kisplyx se ne sme dajati ženskam, ki dojijo.
English: This means that it blocks the activity of enzymes known as tyrosine kinases.
Slovenian: To pomeni, da zavira delovanje določenih encimov, imenovanih tirozin kinaze.
English: The dose of Kisplyx should be decreased in patients with severely reduced kidney or liver function.
Slovenian: Odmerek zdravila Kisplyx je treba zmanjšati pri bolnikih z močno zmanjšanim delovanjem ledvic ali jeter.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kisplyx have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Kisplyx upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Kisplyx, used in combination with everolimus, was shown to significantly improve the time these patients lived without their disease getting worse.
Slovenian: Za zdravilo Kisplyx, uporabljeno v kombinaciji z everolimusom, je bilo ugotovljeno, da znatno izboljša čas, ki so ga živeli ti bolniki, ne da bi se jim bolezen poslabšala.
English: Why is Kisplyx approved?
Slovenian: Zakaj je bilo zdravilo Kisplyx odobreno?
English: Previously treated patients with advanced renal cell carcinoma have poor outcomes and a high unmet medical need.
Slovenian: Predhodno zdravljeni bolniki z napredovalim karcinomom ledvičnih celic imajo slabo prognozo in veliko neizpolnjeno zdravstveno potrebo.
English: These enzymes can be found in certain receptors (such as VEGF, FGFR, PDGF, KIT and RET receptors) in cancer cells, where they activate several processes including cell division and the growth of new blood vessels.
Slovenian: Ti encimi so prisotni v nekaterih receptorjih (kot so receptorji VEGF, FGFR, PDGF, KIT in RET) v rakavih celicah, v katerih spodbujajo številne procese, vključno z delitvijo celic in rastjo novih žil.
English: For more information about treatment with Kisplyx, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Kisplyx preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Kisplyx has been investigated in one main study involving 153 adults with advanced renal cell carcinoma that had got worse despite treatment with a VEGF inhibitor.
Slovenian: Zdravilo Kisplyx je bilo raziskano v eni glavni študiji pri 153 odraslih z napredovalim karcinomom ledvičnih celic, ki se je poslabšal kljub zdravljenju z zaviralcem VEGF.
English: The most common side effects with Kisplyx, when used in combination with everolimus or alone and which may affect more than 3 in 10 people, are diarrhoea, high blood pressure, tiredness, loss of appetite and weight, vomiting, nausea (feeling sick), proteinuria (protein in the urine), stomatitis (inflammation of the lining of the mouth), headache, dysphonia (speech disturbances), palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome, which involves rash and numbness on the palms and soles), peripheral oedema (swelling, especially of the ankles and feet) and hypercholesterolemia (high levels of cholesterol [type of fat] in the blood).
Slovenian: Najpogostejši neželeni učinki zdravila Kisplyx, ko se uporablja v kombinaciji z everolimusom ali samostojno in ki se lahko pojavijo pri več kot 3 bolnikih od 10, so driska, visok krvni tlak, utrujenost, izguba teka in zmanjšanje telesne mase, bruhanje, navzea (slabost), proteinurija (beljakovine v urinu), stomatitis (vnetje ustne sluznice), glavobol, disfonija (motnje govora), sindrom palmarno-plantarne eritrodizestezije (sindrom roka-noga, ki vključuje rdečino in odrevenelost dlani in podplatov), periferni edem (otekanje, še posebej gležnjev in stopal) in hiperholesterolemija (visoka raven holesterola [vrsta maščob] v krvi).
English: The most important serious side effects are kidney failure and reduced kidney function; problems with the heart and circulation such as heart failure and blood clots in the arteries leading to stroke or heart attack; bleeding in the brain or bleeding of a tumour within the skull; a syndrome known as ‘posterior reversible encephalopathy syndrome' characterised by headache, confusion, fits and loss of vision; and liver failure.
Slovenian: Najpomembnejši resni neželeni učinki so odpoved ledvic in oslabljeno delovanje ledvic; težave s srcem in krvnim obtokom, kot sta srčno popuščanje in krvni strdki v arterijah, kar lahko privede do kapi ali srčnega napada; krvavitev v možganih ali krvavitev tumorja znotraj lobanje; sindrom posteriorne reverzibilne encefalopatije, za katerega so značilni glavobol, zmedenost, napadi in izguba vida; ter odpoved jeter.
English: Kisplyx is used together with another cancer medicine called everolimus.
Slovenian: Zdravilo Kisplyx se uporablja skupaj z drugim zdravilom za zdravljenje raka, imenovanim everolimus.
English: The main measure of effectiveness was how long the patients lived without their disease getting worse (progression-free survival).
Slovenian: Glavno merilo učinkovitosti je bilo preživetje bolnikov brez napredovanja bolezni.
English: The safety of Kisplyx used in combination with everolimus is similar to that of these medicines when used individually, and side effects are considered manageable.
Slovenian: Varnost zdravila Kisplyx, uporabljenega v kombinaciji z everolimusom, je podobna varnosti pri samostojni uporabi teh dveh zdravil, neželeni učinki pa so ocenjeni kot obvladljivi.
English: Kisplyx is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have been previously treated with a type of cancer medicine called a ‘vascular endothelial growth factor (VEGF) inhibitor'.
Slovenian: Zdravilo Kisplyx je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje odraslih z napredovalim karcinomom ledvičnih celic (vrsto ledvičnega raka), ki so predhodno bili zdravljeni z zdravilom za zdravljenje raka, imenovanim inhibitor rastnega faktorja vaskularnega endotelija (vascular endothelial growth factor - VEGF).
English: The study compared the combination of Kisplyx and everolimus with Kisplyx or everolimus alone.
Slovenian: Študija je primerjala uporabo kombinacije zdravila Kisplyx in everolimusa z uporabo samo zdravila Kisplyx ali everolimusa.
English: For practical information about using Kisplyx, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Kisplyx naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: The active substance in Kisplyx, lenvatinib, is a ‘tyrosine-kinase inhibitor'.
Slovenian: Zdravilna učinkovina v zdravilu Kisplyx, lenvatinib, je zaviralec tirozin kinaze.
English: How does Kisplyx work?
Slovenian: Kako zdravilo Kisplyx deluje?
English: For further information, see the package leaflets for Kisplyx and the medicine containing everolimus.
Slovenian: Za več informacij glejte navodila za uporabo zdravila Kisplyx in zdravila, ki vsebuje everolimus.
English: For the list of all side effects reported with everolimus, see the package leaflet of the medicine containing everolimus.
Slovenian: Za seznam vseh neželenih učinkov, o katerih so poročali pri uporabi everolimusa, glejte navodilo za uporabo zdravila, ki vsebuje everolimus.
English: The dose of Kisplyx may need to be reduced or treatment stopped temporarily if certain side effects occur.
Slovenian: Če se pojavijo določeni drugi neželeni učinki, je odmerek zdravila Kisplyx morda treba zmanjšati ali začasno prekiniti zdravljenje.
English: For the full list of all side effects reported with Kisplyx, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Kisplyx, glejte navodilo za uporabo.
English: How is Kisplyx used?
Slovenian: Kako se zdravilo Kisplyx uporablja?
English: Kisplyx contains the active substance lenvatinib.
Slovenian: Zdravilo Kisplyx vsebuje zdravilno učinkovino lenvatinib.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19 January 2007
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 19. januar 2007
English: If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.
Slovenian: Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje (npr. laktozo), se pred začetkom jemanja tega zdravila posvetujte s svojim zdravnikom.
English: They may cause a decrease in placental perfusion, foetal electrolyte disturbances and possibly other reactions that have occurred in the adults.
Slovenian: Povzročijo lahko zmanjšano perfuzijo placente, elektrolitske motnje pri plodu in mogoče tudi druge reakcije, ki se pojavljajo pri odraslih.
English: It is also important to tell your doctor if you are taking other medicines to reduce your blood pressure, steroids, medicines to treat cancer, pain killers or arthritis medicines.
Slovenian: Pomembno je, da zdravnika obvestite tudi, če jemljete druga zdravila za zniževanje krvnega tlaka, kortikosteroide, zdravila za zdravljenje raka, lajšanje bolečin ali zdravila proti artritisu.